<DOC>
	<DOCNO>NCT00023660</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving radiation therapy different way combine chemotherapy may kill tumor cell . Celecoxib may slow growth cervical cancer stop blood flow tumor . PURPOSE : Phase I/II trial study effectiveness radiation therapy plus celecoxib , fluorouracil , cisplatin treat patient locally advanced cervical cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Celecoxib , Fluorouracil , Cisplatin Patients With Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine treatment-related toxicity rate patient locally advanced cervical cancer treat external beam radiotherapy brachytherapy concurrently celecoxib , fluorouracil , cisplatin . - Determine whether regimen increase locoregional control rate , distant control , disease-free survival , overall survival patient . - Determine whether first-failure pattern patient treat regimen change compare historical control . OUTLINE : This multicenter study . Patients undergo external beam pelvic radiotherapy daily five day week 5 week begin day 1 . Within 8 week , patient undergo low-dose high-dose brachytherapy . Patients also receive concurrent chemotherapy comprise fluorouracil IV continuously day 2-5 , 23-26 , 44-47 cisplatin IV 4 hour day 1 , 22 , 43 . Oral celecoxib administer twice daily begin day 1 continue 12 month . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 83 patient accrue study within 1.5 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous , adenocarcinoma , adenosquamous carcinoma cervix Stage IIBIVA OR Stage IBIIA pelvic node metastasis and/or tumor size least 5 cm No small cell , carcinoid , glassy cell , clear cell , adenoid cystic disease No metastatic disease outside pelvis No paraaortic disease PATIENT CHARACTERISTICS : Age : 18 85 Performance status : Zubrod 02 Life expectancy : At least 6 month Hematopoietic : WBC least 3,000/mm^3 Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Calcium great 1.3 time ULN Cardiovascular : No severe heart disease Other : Not pregnant nursing Negative pregnancy test HIV negative No prior allergy sulfonamide nonsteroidal antiinflammatory drug ( NSAIDs ) No prior hypersensitivity celecoxib component formulation No medical psychiatric illness would preclude study No active gastrointestinal ( GI ) ulcer , GI bleeding , inflammatory bowel disease No prior malignancy within past 5 year except cutaneous basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No recent prior celecoxib cyclooxygenase2 inhibitor Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis except transvaginal radiotherapy control bleed Surgery : No prior surgery cervical cancer except biopsy Other : No concurrent phenytoin lithium No concurrent NSAIDs</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>